Novo Nordisk A/S
NONOF
$49.45
-$0.07-0.14%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.34B | 11.74B | 11.69B | 11.02B | 12.25B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.34B | 11.74B | 11.69B | 11.02B | 12.25B |
| Cost of Revenue | 2.21B | 2.27B | 1.95B | 1.82B | 1.72B |
| Gross Profit | 10.13B | 9.48B | 9.74B | 9.20B | 10.52B |
| SG&A Expenses | 2.67B | 2.47B | 2.87B | 2.27B | 2.90B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -12.63M | -- | 3.50M | -1.97M | 34.01M |
| Total Operating Expenses | 6.84B | 6.54B | 6.60B | 5.54B | 5.49B |
| Operating Income | 5.49B | 5.21B | 5.09B | 5.47B | 6.76B |
| Income Before Tax | 5.33B | 4.00B | 5.14B | 5.22B | 5.08B |
| Income Tax Expenses | 1.14B | 863.28M | 1.11B | 1.13B | 1.05B |
| Earnings from Continuing Operations | 4.19B | 3.13B | 4.03B | 4.10B | 4.03B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.19B | 3.13B | 4.03B | 4.10B | 4.03B |
| EBIT | 5.49B | 5.21B | 5.09B | 5.47B | 6.76B |
| EBITDA | 5.71B | 5.72B | 5.73B | 6.01B | 6.84B |
| EPS Basic | 0.94 | 0.71 | 0.91 | 0.92 | 0.91 |
| Normalized Basic EPS | 0.82 | 0.77 | 0.72 | 0.74 | 0.93 |
| EPS Diluted | 0.94 | 0.70 | 0.91 | 0.92 | 0.91 |
| Normalized Diluted EPS | 0.82 | 0.77 | 0.72 | 0.73 | 0.92 |
| Average Basic Shares Outstanding | 4.44B | 4.44B | 4.44B | 4.44B | 4.45B |
| Average Diluted Shares Outstanding | 4.45B | 4.45B | 4.45B | 4.45B | 4.46B |
| Dividend Per Share | 1.24 | 0.00 | 0.57 | -- | 1.13 |
| Payout Ratio | 0.00% | 83.29% | -- | 121.49% | 0.00% |